The precision medical industry has grown into a profitable industry in the United States. It is estimated that by 2019, the global market will only reach 5.6 billion US dollars with a diagnostic market, with a compound annual growth rate of 18.1%. As for genotyping, it is expected to be included in standard clinical diagnostic methods by 2020. Since the introduction of the Precision Medical Plan, the FDA and the National Institutes of Health (NIH) have collaborated and coordinated to launch the open FDA Digital Strategic Plan to ensure that researchers access FDA public data through a digital application programming interface (API) to encourage innovation and promote Technological development. Research shows that in the past five years, the R&D department's investment in personalized medicine has doubled, and it is expected to increase by 30% in the next three years. In the future, personalized drug-producing drug research and development will account for 69%. Through the clinical diagnosis of precision medicine, the patient's genetic polymorphisms and gene mutations can be detected quickly and easily. In addition, point-of- care (POC) and portable medical devices are constantly emerging. The development of next-generation sequencing technology (NGS) has facilitated the use of large-scale genomic fragments or whole-genome sequencing in clinical diagnostics. In April 2015, the FDA issued a guidance document to launch the Device Fast Track project to promote effective management of medical device regulatory strategies to integrate advanced genomic technologies to address complex clinical needs. Currently, the FDA has completed the approval of 23 accompanying diagnoses; approved 147 drugs targeting 50 disease biomarkers, including cystic fibrosis, cancer, mental illness, infectious diseases, cholesterol diseases, etc.; Personalized nucleic acid testing, published more than 24 guidance documents. The FDA's first approved NGS medical device is a cystic fibrosis test. In November 2013, Illumina announced the approval of the first NGS platform, including the MiSeqDx System and the companion MiSeqDx Universal Kit 1.0 sequencing reagent, which can be used for targeted sequencing of human genomic DNA in peripheral blood samples. Two in vitro diagnostics for the detection of transmembrane transduction regulator gene mutations in cystic fibrosis are also licensed. These multi-faceted genomic cystic fibrosis targeted tests can be used to screen adult carriers, perform confirmatory testing of newborns and children, and diagnose suspected patients. In February 2015, the FDA approved the marketing rights of the first direct-to-consumer genetic testing product, 23andMe's Bloom Syndrome Carrier Test, for screening for autosomal recessive carriers in Bloom's syndrome. Contains genetic variants of the genetic disease. Silicone Film Dressing,Soft Comfortable Foam Dressing,Skin-Friendly Silicone Foam Dressing,Superabsorbent Silicone Foam Dressing Zhende Medical Co.,Ltd , https://www.zhendemedicals.com